Whole Brain Radiotherapy in Combination With Gefitinib (Iressa) or Temozolomide (Temodal) for Brain Metastases From Non-Small Lung Cancer (NSCLC) A Randomized Phase II Trial.

Trial Profile

Whole Brain Radiotherapy in Combination With Gefitinib (Iressa) or Temozolomide (Temodal) for Brain Metastases From Non-Small Lung Cancer (NSCLC) A Randomized Phase II Trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2012

At a glance

  • Drugs Gefitinib; Temozolomide
  • Indications Brain metastases; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jun 2012 Actual end date (1 Nov 2010) added as reported by ClinicalTrials.gov.
    • 15 Nov 2011 Results published in the European Journal of Cancer.
    • 07 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top